Want to see SLN full AI Analyst Report?
SLN Stock Chart & Stats
$7.53
-$0.25(-3.72%)
At close: 4:00 PM EST
$7.53
-$0.25(-3.72%)
Day’s Range― - ―
52-Week Range$4.19 - $11.06
Previous CloseN/A
Volume50.54K
Average Volume (3M)101.05K
Market Cap
$495.96M
Enterprise Value$313.78M
Total Cash (Recent Filing)$70.08M
Total Debt (Recent Filing)$136.00K
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.32
Shares Outstanding47,234,610
10 Day Avg. Volume169,902
30 Day Avg. Volume101,050
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.61
Price to Sales (P/S)513.72
P/FCF Ratio-4.61
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue340.51
Enterprise Value/Gross Profit512.62
Enterprise Value/Ebitda-4.02
Forecast
1Y Price Target
$42.33Price Target Upside462.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.53
Revenue Forecast (FY)$3.35M
Bulls Say, Bears Say
Bulls Say
Proprietary GalNAc SiRNA Delivery PlatformSilence’s GalNAc-based delivery toolbox is a durable competitive asset for liver-targeted RNAi. It raises technical barriers to entry, improves partner appeal for licensing deals, and underpins multiple pipeline programs in cardiometabolic and hepatic indications, supporting sustained R&D and collaboration opportunities.
Positive Phase 1 Divesiran Clinical DataRobust Phase 1 safety and durable efficacy signals for divesiran, with large phlebotomy reductions and QoL gains, materially de-risk the program ahead of Phase 2 topline. This strengthens the company’s potential first-in-class positioning in polycythemia vera and enhances long-term commercial and partnership prospects if Phase 2 confirms results.
Low Financial LeverageNear-zero debt gives Silence financial flexibility to fund clinical programs, negotiate deals, or access capital without heavy interest burden. Low leverage reduces insolvency risk during multi-year development cycles common in biotech and supports the company’s ability to pursue strategic options or partnerships over the next several quarters.
Bears Say
Sustained Negative Operating And Free Cash FlowPersistent, large negative operating and free cash flows mean the company must continually raise capital or secure partner funding to progress trials. This ongoing burn limits internal optionality, increases dilution or financing risk, and constrains the pace and scope of development absent near-term material financing or milestone receipts.
Small, Volatile Revenue BaseA very small and unstable revenue stream reduces self-funding capacity and makes the business reliant on milestone, licensing, or equity raises. Structural dependence on non-recurring partner payments increases execution risk and ties program progress to successful deal-making rather than predictable product cash flows.
Eroding Equity And Persistently Negative ROEMeaningful equity erosion and negative ROE reflect sustained value destruction from operating losses. This undermines shareholder capital over time, can weaken investor confidence, and may raise the cost of future capital, limiting the company’s ability to finance growth without significant dilution or unfavorable terms.
Silence Therapeutics News
SLN FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was $4.19 and its highest was $11.06 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is $495.96M.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on May 07, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.129 by $0.019.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 47,234,610 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.129. Following the earnings report the stock price went down -5.571%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in SLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Silence Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.33 (462.20% Upside)
$42.33 (462.20% Upside)
Hedge Fund Trend
Decreased
By 70.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.4%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-64.86%
12-Months-Change
Fundamentals
Return on Equity
-121.71%
Trailing 12-Months
Asset Growth
-37.87%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
SLN Stock 12 Month Forecast
Average Price Target
$42.33
▲(462.20% Upside)
Technical Analysis
Ownership Overview
22.15%
Insiders
0.10% Mutual Funds
32.00% Other Institutional Investors
45.18% Public Companies and
Individual Investors